跳至主要内容
临床试验/NCT00814567
NCT00814567Unknown不适用

Randomised Trial Testing Intensity Modulated and Partial Organ Radiotherapy After Breast Conservation Surgery for Early Breast Cancer

Institute of Cancer Research, United Kingdom2 个研究点 分布在 1 个国家目标入组 2,018 人开始时间: 2007年5月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
发起方
入组人数
2,018
试验地点
2
主要终点
Local tumor control in the ipsilateral breast (i.e., true recurrence plus new primary tumor) as confirmed by cytological or histological assessment

研究概览

简要总结

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether intensity-modulated radiation therapy is more effective than standard radiation therapy in treating patients with early-stage breast cancer.

PURPOSE: This randomized phase III trial is comparing radiation therapy regimens in treating women with early-stage breast cancer who have undergone breast-conservation surgery.

详细描述

OBJECTIVES:

  • To test partial breast radiotherapy using intensity-modulated techniques following complete local tumor excision in women with low-risk, early stage breast cancer.

OUTLINE: This is a multicenter study.

Patients are stratified according to center (not participating in sub-studies vs participating in sub-studies). Patients are randomized to 1 of 3 treatment arms.

  • Arm I (control): Patients undergo standard whole breast radiotherapy once daily on days 1-5 (15 fractions) for 3 weeks.
  • Arm II: Patients undergo reduced whole breast radiotherapy (15 fractions) and standard partial breast radiotherapy (15 fractions) once daily on days 1-5 for 3 weeks.
  • Arm III: Patients undergo standard partial breast radiotherapy once daily on days 1-5 (15 fractions) for 3 weeks.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
50 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • No primary endocrine therapy as a replacement for surgery
  • No concurrent chemoradiotherapy

排除标准

  • 未提供

研究组 & 干预措施

Arm I (control)

Active Comparator

Patients undergo standard whole breast radiotherapy once daily on days 1-5 for 3 weeks.

干预措施: radiation therapy (Radiation)

Arm II

Experimental

Patients undergo reduced whole breast radiotherapy and standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.

干预措施: radiation therapy (Radiation)

Arm III

Experimental

Patients undergo standard partial breast radiotherapy once daily on days 1-5 for 3 weeks.

干预措施: radiation therapy (Radiation)

结局指标

主要结局

Local tumor control in the ipsilateral breast (i.e., true recurrence plus new primary tumor) as confirmed by cytological or histological assessment

时间窗: 5 years

次要结局

  • Location of tumor relapse(5 years)
  • Quality of life as assessed by EORTC QLQ C-30, EORTC QLQ-BR23, BIS, and HADS questionnaires in a subset of patients at baseline, 6 months, and 1, 2, and 5 years(5 years)
  • Contralateral primary breast cancer or other primary tumors as confirmed by cytological or histological assessment(5 years)
  • Regional and distant metastases(5 years)
  • Late adverse effects in normal tissue normal tissues as determined periodically by photographic assessments (in a subset of patients), physician assessments, and patient self-assessments(5 years)
  • Cost-effectiveness as assessed by EQ-5D questionnaire at baseline, 6 months, and 1, 2, and 5 years(10 years)

研究者

发起方
Institute of Cancer Research, United Kingdom
申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验